| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14712598.4.7.1093 |
| P698 | PubMed publication ID | 15268676 |
| P2093 | author name string | Terence R Flotte | |
| Thomas J Conlon | |||
| P2860 | cites work | Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism | Q24515072 |
| Adeno-associated virus type 2-mediated gene transfer: role of cellular FKBP52 protein in transgene expression | Q24529167 | ||
| Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy | Q24535690 | ||
| Site-specific integration by adeno-associated virus | Q24558738 | ||
| Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy | Q28281738 | ||
| Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection | Q30923081 | ||
| In vitro selection of viral vectors with modified tropism: the adeno-associated virus display | Q33187644 | ||
| Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes | Q33793801 | ||
| Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts | Q33796712 | ||
| Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells | Q34090326 | ||
| The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity | Q34124491 | ||
| A p5 integration efficiency element mediates Rep-dependent integration into AAVS1 at chromosome 19. | Q34156171 | ||
| Rescue and replication signals of the adeno-associated virus 2 genome | Q34301032 | ||
| Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. | Q34433170 | ||
| AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection | Q34486863 | ||
| Production of clinical-grade recombinant adeno-associated virus vectors | Q35012878 | ||
| Adeno-associated viruses undergo substantial evolution in primates during natural infections | Q35022838 | ||
| Effect of DNA-dependent protein kinase on the molecular fate of the rAAV2 genome in skeletal muscle | Q35054512 | ||
| Receptor targeting of adeno-associated virus vectors | Q35165723 | ||
| From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy | Q35180997 | ||
| Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy | Q35799349 | ||
| Site-specific integration by adeno-associated virus is directed by a cellular DNA sequence | Q35829692 | ||
| Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein | Q35943644 | ||
| Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus | Q36159178 | ||
| Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics | Q36460379 | ||
| DNA-dependent PK inhibits adeno-associated virus DNA integration | Q36604872 | ||
| Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors | Q36734619 | ||
| Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle | Q39589663 | ||
| Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors | Q39589898 | ||
| Enhancement of muscle gene delivery with pseudotyped adeno-associated virus type 5 correlates with myoblast differentiation. | Q39606539 | ||
| Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors. | Q39682659 | ||
| Infection of purified nuclei by adeno-associated virus 2. | Q40775943 | ||
| Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody | Q40969562 | ||
| Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration | Q41431346 | ||
| Gene expression from adeno-associated virus vectors in airway epithelial cells | Q41606833 | ||
| Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. | Q41722852 | ||
| Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain | Q42280576 | ||
| Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors | Q43716886 | ||
| Intramuscular administration of recombinant adeno-associated virus 2 alpha-1 antitrypsin (rAAV-SERPINA1) vectors in a nonhuman primate model: safety and immunologic aspects | Q44136395 | ||
| Efficient trans-splicing in the retina expands the utility of adeno-associated virus as a vector for gene therapy. | Q44305893 | ||
| Self-complementary adeno-associated virus serotype 2 vector: global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain | Q44686125 | ||
| In vivo trans-splicing of 5' and 3' segments of pre-mRNA directed by corresponding DNA sequences delivered by gene transfer | Q44686129 | ||
| Recombinant adeno-associated virus-mediated alpha-1 antitrypsin gene therapy prevents type I diabetes in NOD mice | Q44719693 | ||
| Transgene expression after rep-mediated site-specific integration into chromosome 19. | Q45019591 | ||
| Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies | Q45709087 | ||
| Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo | Q45709105 | ||
| Structure determination of adeno-associated virus 2: three complete virus particles per asymmetric unit | Q45723313 | ||
| Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors | Q45735547 | ||
| Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization | Q45742577 | ||
| Quantitative analysis of the packaging capacity of recombinant adeno-associated virus | Q45766162 | ||
| Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing | Q45863479 | ||
| Targeted transgene integration into transgenic mouse fibroblasts carrying the full-length human AAVS1 locus mediated by HSV/AAV rep(+) hybrid amplicon vector. | Q45864772 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | gene therapy | Q213901 |
| vector-borne disease | Q2083837 | ||
| P304 | page(s) | 1093-1101 | |
| P577 | publication date | 2004-07-01 | |
| P1433 | published in | Expert Opinion on Biological Therapy | Q5421201 |
| P1476 | title | Recombinant adeno-associated virus vectors for gene therapy | |
| P478 | volume | 4 |
| Q33864423 | A shortened adeno-associated virus expression cassette for CFTR gene transfer to cystic fibrosis airway epithelia. |
| Q34843762 | A simple method to increase the transduction efficiency of single-stranded adeno-associated virus vectors in vitro and in vivo. |
| Q40205113 | Adeno-associated virus 2-mediated gene transfer: role of a cellular serine/threonine protein phosphatase in augmenting transduction efficiency |
| Q34795088 | Capsid serotype and timing of injection determines AAV transduction in the neonatal mice brain |
| Q35636782 | Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome |
| Q35638200 | Experience with experimental biological treatment and local gene therapy in Sjogren's syndrome: implications for exocrine pathogenesis and treatment |
| Q80448411 | Gene therapy for arthritis |
| Q36751590 | Gene therapy for type 1 diabetes: is it ready for the clinic? |
| Q36240196 | Gene therapy progress and prospects: reprograming gene expression by trans-splicing |
| Q35014865 | Hybrid adeno-associated viral vectors utilizing transposase-mediated somatic integration for stable transgene expression in human cells |
| Q45862137 | Intraperitoneal gene therapy by rAAV provides long-term survival against epithelial ovarian cancer independently of survivin pathway |
| Q45863257 | NOD mouse model for Sjögren's syndrome: lack of longitudinal stability |
| Q33832799 | Optimized adeno-associated virus (AAV)-protein phosphatase-5 helper viruses for efficient liver transduction by single-stranded AAV vectors: therapeutic expression of factor IX at reduced vector doses |
| Q36144935 | Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice |
| Q45370683 | Recombinant adeno-associated virus-mediated gene transfer for the potential therapy of adenosine deaminase-deficient severe combined immune deficiency. |
| Q37005491 | Role of cellular FKBP52 protein in intracellular trafficking of recombinant adeno-associated virus 2 vectors |
| Q35972733 | Self-Complementary Adeno-Associated Virus Vectors Improve Transduction Efficiency of Corneal Endothelial Cells |
| Q38692453 | Somatic correction of junctional epidermolysis bullosa by a highly recombinogenic AAV variant. |
| Q39979752 | Strategies for improving the transduction efficiency of single-stranded adeno-associated virus vectors in vitro and in vivo |
| Q36966036 | The promise of gene therapy for the treatment of alpha-1 antitrypsin deficiency |
| Q42582773 | Treatment of glioblastoma multiforme cells with temozolomide-BioShuttle ligated by the inverse Diels-Alder ligation chemistry |
Search more.